financetom
Business
financetom
/
Business
/
IDFC First Bank Q2 result: Net profit up nearly 50% at Rs 152 crore, income jumps to Rs 4,880 crore
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
IDFC First Bank Q2 result: Net profit up nearly 50% at Rs 152 crore, income jumps to Rs 4,880 crore
Oct 30, 2021 9:55 AM

IDFC First Bank on Saturday reported a nearly 50 percent jump in its standalone net profit at Rs 151.74 crore in the quarter ended September 2021.

The bank had posted a net profit of Rs 101.41 crore in the same quarter a year ago. Sequentially, there was a net loss of Rs 630 crore in the quarter ended June 2021.

IDFC First Bank's total income during July-September of FY22 rose to Rs 4,880.29 crore, as against Rs 4,090.87 crore in the same quarter of FY21, it said in a regulatory filing.

The interest income stood at Rs 4,100.58 crore, up from Rs 3,924.86 crore. Bank's provisioning for bad loans and contingencies were raised substantially for the September 2021 quarter at Rs 474.95 crore as bad loans moved up.

The bank had parked aside Rs 213.40 crore towards the same in the year-ago period. There was impairment on the asset quality with the gross non-performing assets (NPAs or bad loans) spiking to 4.27 percent of the gross advances by end of Q2 FY22, as against 1.62 percent by the end of the same period in FY'21. Value-wise, it stood at Rs 4,485.53 crore, as against Rs 1,486.11 crore.

Net NPAs too rose to 2.09 per cent (Rs 2,150.34 crore) from 0.43 per cent (Rs 390.95 crore).

However, the bank said that gross and net NPAs for the quarter ended September 30, 2020 are not comparable as an interim Supreme Court order had directed banks that accounts that were not declared as NPA till August 31, 2020, shall not be declared as NPA. The order relates to the pandemic-driven stress to customers last year.

On consolidated basis, the bank posted a net profit of Rs 110.95 crore, slightly up from Rs 109.03 crore. Total income rose to Rs 4,830.14 crore from Rs 4,090.91 crore.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Exclusive-Sanctions delay to Russian zinc mine causes supply miscalculation, sources say
Exclusive-Sanctions delay to Russian zinc mine causes supply miscalculation, sources say
Nov 3, 2024
LONDON (Reuters) - Western sanctions on Russia's zinc miner Ozernoye have left it struggling to replace equipment needed to ramp up output, three sources with knowledge of the matter said, meaning mined zinc supply forecasts for 2025 are likely to be too high. Without Ozernoye's substantial contribution to global mined zinc supply next year, a shortage of zinc concentrate -...
Swiss chemical maker Sika's nine-month sales rise 5.5%
Swiss chemical maker Sika's nine-month sales rise 5.5%
Nov 3, 2024
Oct 25 (Reuters) - Swiss industrial and construction chemicals company Sika reported a 5.5% increase in sales for the first nine months of 2024 on Friday, and confirmed its outlook for the year. The company, whose chemical additives are used to strengthen and waterproof building materials in walls, floors and roofs, said sales rose to 8.91 billion Swiss francs ($10.29...
Monopar Therapeutics, Intellia Therapeutics, Capri Holdings, Western Digital, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
Monopar Therapeutics, Intellia Therapeutics, Capri Holdings, Western Digital, And Tesla: Why These 5 Stocks Are On Investors' Radars Today
Nov 3, 2024
The U.S. stock market exhibited a mixed performance on Thursday. The Nasdaq Composite gained over 130 points, while the Dow traded down 0.3% to 42,374.36. The S&P 500 also rose, gaining 0.2% to 5,809.86. These are the top stocks that gained the attention of retail traders and investors throughout the day: Monopar Therapeutics Inc. ( MNPR ) skyrocketed by 605.40%...
Goldman-backed drug developer Septerna raises $288 mln in US IPO
Goldman-backed drug developer Septerna raises $288 mln in US IPO
Nov 3, 2024
* Septerna now offering 16 mln shares vs 15.3 mln shares earlier * Sets IPO price at $18 a share * Drug developer backed by Goldman, Third Rock Ventures * Listing follows a spate of biotech IPOs since September (Adds pricing of IPO in paragraphs 1-2, background in paragraph 3) By Arasu Kannagi Basil Oct 24 (Reuters) - Biotech firm...
Copyright 2023-2025 - www.financetom.com All Rights Reserved